Cytotoxicity Evaluation of Ammonia-Modified Graphene Oxide Particles in Lung Cancer Cells and Embryonic Stem Cells

被引:12
|
作者
Keremidarska-Markova, Milena [1 ,2 ]
Hristova-Panusheva, Kamelia [1 ]
Andreeva, Tonya [1 ]
Speranza, Giorgio [3 ]
Wang, Dayong [4 ]
Krasteva, Natalia [1 ]
机构
[1] Bulgarian Acad Sci, Inst Biophys & Biomed Engn, BU-1113 Sofia, Bulgaria
[2] Sofia Univ St Kliment Ohridski, Fac Biol, Sofia 1164, Bulgaria
[3] Univ Trento, I-38122 Trento, Italy
[4] Southeast Univ, Med Sch, Nanjing 210096, Jiangsu, Peoples R China
关键词
SILVER NANOPARTICLES; BIOCOMPATIBILITY; DELIVERY; SURFACE; BIODISTRIBUTION; TOXICITY; MICE;
D O I
10.1155/2018/9571828
中图分类号
O469 [凝聚态物理学];
学科分类号
070205 ;
摘要
Potential toxicity of graphene oxide (GO) is a subject of increasing research interest in the recent years. Here, we have evaluated the cytotoxicity of ammonia-modified GO (GO-NH2) and pristine GO particles in human lung cancer cells, A549 and embryonic stem cells, Lep3 exposed to different particles concentrations (0.1,1,10, 20, and 50 mu g/ml) for different times (24 and 48h). Compared with GO, GO-NH2 particles possessed smaller size, positive surface charge and higher thickness. An increased propensity to aggregation in cell cultures was also found for GO-NH2 particles. Cytotoxicity evaluation revealed that GO-NH2 particles are more toxic than pristine GO. Applied at concentrations of 10, 20 and 50 mu g/ml for 24h they affect significantly cell morphology of viable embryonic stem cells whereas human lung cancer A549 cells seem to be relatively more resistant to short-time exposure. After 48h exposure however cell proliferation of A549 cells was strongly suppressed in a dose-dependent manner while the proliferation ability of embryonic stem cells was not affected. These results suggested that both GO particles exert different degree of cytotoxicity which is time, dose and cell dependent. In general, ammonia-modified GO particles are more toxic than the pristine GO which should be taken into account for future biomedical applications.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Characterization and evaluation of human embryonic stem cells
    Xu, Chunhui
    STEM CELL TOOLS AND OTHER EXPERIMENTAL PROTOCOLS, 2006, 420 : 18 - 37
  • [22] Graphene Oxide Nanocolloids Induce Autophagy-Lysosome Dysfunction in Mouse Embryonic Stem Cells
    Wei, Min
    Fu, Zhenfa
    Wang, Che
    Zheng, Wei
    Li, Song
    Le, Weidong
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2019, 15 (02) : 340 - 351
  • [23] Graphene Oxide as Scaffolds for Stem Cells: An Overview
    Duran, M.
    Luzo, A. C. M.
    de Souza, J. G.
    Favaro, W. J.
    Garcia, P.
    Duran, N.
    CURRENT MOLECULAR MEDICINE, 2017, 17 (09) : 619 - 626
  • [24] MicroRNA reins in embryonic and cancer stem cells
    Mallick, Bibekanand
    Chakrabarti, Jayprokas
    Ghosh, Zhumur
    RNA BIOLOGY, 2011, 8 (03) : 415 - 426
  • [25] Signaling Pathways in Cancer and Embryonic Stem Cells
    Oliver Dreesen
    Ali H. Brivanlou
    Stem Cell Reviews, 2007, 3 : 7 - 17
  • [26] MicroRNAs in Human Embryonic and Cancer Stem Cells
    Navarro, Alfons
    Monzo, Mariano
    YONSEI MEDICAL JOURNAL, 2010, 51 (05) : 622 - 632
  • [27] Signaling pathways in cancer and embryonic stem cells
    Dreesen, Oliver
    Brivanlou, Ali H.
    STEM CELL REVIEWS, 2007, 3 (01): : 7 - 17
  • [28] Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells
    Gauthaman, K.
    Manasi, N.
    Bongso, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (06) : 962 - 973
  • [29] The MAPK/ERK pathway among colon cancer cells, colon cancer stem cells, embryonic stem cells and normal cells
    Apostolou, P.
    Toloudi, M.
    Chatziioannou, M.
    Ioannou, E.
    Kourtidou, E.
    Papasotiriou, I
    ONKOLOGIE, 2013, 36 : 66 - 66
  • [30] Cancer immunotherapy by genetically modified embryonic stem cell-derived dendritic cells
    Matsuyoshi, H
    Senju, S
    Hirata, S
    Yoshitake, Y
    Fukuma, D
    Motomura, Y
    Nishimura, Y
    IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION, 2004, : 487 - 491